To validate the cytotoxicity of these GM NK-92 cells, these cells were tested against sarcoma explants and it was reported that DNAM-1+ GM NK-92 cells were able to significantly increase cytotoxicity compared to wild type NK-92 cells while no significant effect was observed with NKG2D+ GM NK-92 cells. This evidence concerns the gene CD226 and sarcoma.